(Q34258670)

31 July 2017

Monoclonal antibody strategies to block angiogenesis (English)

1 reference

31 July 2017

1 reference

1 reference

1 reference

D J. Hicklin

1

1 reference

31 July 2017

L Witte

2

1 reference

31 July 2017

Z Zhu

3

1 reference

31 July 2017

F Liao

4

1 reference

31 July 2017

Y Wu

5

1 reference

31 July 2017

Y Li

6

1 reference

31 July 2017

P Bohlen

7

1 reference

31 July 2017

1 May 2001

1 reference

31 July 2017

1 reference

31 July 2017

6

1 reference

31 July 2017

10

1 reference

31 July 2017

517-528

1 reference

Mechanisms of angiogenesis

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Clinical trials of antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Molecular and biological properties of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

VEGFs, receptors and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Halting angiogenesis suppresses carcinoma cell invasion

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Expression of the avian VEGF receptor homologues Quek1 and Quek2 in blood-vascular and lymphatic endothelial and non-endothelial cells during quail embryonic development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Inhibition of angiogenesis in rats by IL-1 receptor antagonist and selected cytokine antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Role of endogenous basic fibroblast growth factor in the healing of gastric ulcers in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

A freeze-injured skin graft model for the quantitative study of basic fibroblast growth factor and other promoters of angiogenesis in wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Role of an anti-epidermal growth factor receptor in treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Cell adhesion and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

CDw49b/CD29 integrin complex mediates the differentiation of human endothelial cells into capillary-like structures in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Cell adhesion: the molecular basis of tissue architecture and morphogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Vascular endothelial (VE)-cadherin: only an intercellular glue?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

A monoclonal antibody to human angiogenin. Inhibition of ribonucleolytic and angiogenic activities and localization of the antigenic epitope

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Angiogenin antagonists prevent tumor growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Antibody-directed targeting of the vasculature of solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

Suppression of solid tumor growth by a monoclonal antibody against tumor vasculature in rats: involvement of intravascular thrombosis and fibrinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2901759-7

7 January 2021

10.1016/S1359-6446(01)01759-7

Identifiers

DOI

1 reference

release_qqjrzdyr3zgjla5dhwdc2d5dom

31 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qqjrzdyr3zgjla5dhwdc2d5dom

24 November 2022

mapped directly with Wikidata item

1 reference